Terms ending in 2038
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,562,896 | 6-5 FUSED RINGS AS C5a INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,683,294 | 5-5 FUSED RINGS AS C5a INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,384,079 | 6-5 FUSED RINGS AS C5a INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,479,553 | 5-5 FUSED RINGS AS C5a INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,773,091 | 6-5 FUSED RINGS AS C5a INHIBITORS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,919,852 | Immunomodulator Compounds In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,708,326 | Immunomodulator Compounds In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,392,405 | Macrocyclic Immunomodulators In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,059,834 | Macrocyclic Immunomodulators In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,691,985 | Macrocyclic Immunomodulators In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| 4 more term ends in 2038 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.